This pathway can be targeted to reduce the severity of postprandial lipemia in obese, insulin-resistant patients while concurrently reducing fat absorption10 and enhancing peripheral tissue insulin sensitivity.39 Whether these benefits would outweigh the potential risks of targeting this biological pathway remains to be determined. The gene discussed is INS; the disease is hyperlipidemia.